Analysts Set Vigil Neuroscience, Inc. (NASDAQ:VIGL) Target Price at $10.80

Key Points

• Vigil Neuroscience, Inc. has received an average consensus rating of "Hold" from ten brokerages, reflecting a significant downgrade from previous ratings.
• The company's stock currently has an average 1-year price target of $10.80, while recently revised price objectives have lowered as much as to $8.00.
• Vigil Neuroscience reported a quarterly loss with earnings per share at ($0.56), missing analysts' estimates, and is forecasted to post -2.07 earnings per share for the current fiscal year.

Vigil Neuroscience, Inc. (NASDAQ:VIGL - Get Free Report) has earned an average rating of "Hold" from the ten ratings firms that are currently covering the stock, MarketBeat reports. Ten analysts have rated the stock with a hold recommendation. The average 1-year price target among brokers that have issued a report on the stock in the last year is $10.80.

VIGL has been the topic of a number of research reports. Citizens Jmp downgraded shares of Vigil Neuroscience from a "strong-buy" rating to a "hold" rating in a research note on Thursday, May 22nd. JMP Securities reaffirmed a "market perform" rating on shares of Vigil Neuroscience in a research report on Thursday, May 22nd. Jefferies Financial Group lowered shares of Vigil Neuroscience to a "hold" rating in a research note on Thursday, May 22nd. Citigroup downgraded shares of Vigil Neuroscience to a "market perform" rating in a research report on Thursday, May 22nd. Finally, Mizuho cut Vigil Neuroscience from a "strong-buy" rating to a "hold" rating in a research report on Friday, May 23rd.

Institutional Investors Weigh In On Vigil Neuroscience

Hedge funds and other institutional investors have recently modified their holdings of the stock. Cubist Systematic Strategies LLC boosted its position in shares of Vigil Neuroscience by 53.0% during the 4th quarter. Cubist Systematic Strategies LLC now owns 24,120 shares of the company's stock valued at $41,000 after acquiring an additional 8,358 shares in the last quarter. Jane Street Group LLC bought a new position in shares of Vigil Neuroscience in the fourth quarter valued at approximately $83,000. Vanguard Personalized Indexing Management LLC acquired a new stake in Vigil Neuroscience during the 2nd quarter valued at $89,000. Barclays PLC boosted its stake in Vigil Neuroscience by 43.6% in the fourth quarter. Barclays PLC now owns 64,049 shares of the company's stock worth $109,000 after purchasing an additional 19,436 shares in the last quarter. Finally, Northern Trust Corp raised its holdings in shares of Vigil Neuroscience by 29.0% in the fourth quarter. Northern Trust Corp now owns 64,737 shares of the company's stock valued at $110,000 after buying an additional 14,572 shares during the last quarter. Institutional investors and hedge funds own 83.64% of the company's stock.

Vigil Neuroscience Price Performance

Shares of NASDAQ VIGL remained flat at $8.05 during trading on Wednesday. Vigil Neuroscience has a fifty-two week low of $1.31 and a fifty-two week high of $8.10. The company has a market cap of $383.90 million, a P/E ratio of -3.93 and a beta of 3.33. The business has a fifty day moving average of $7.98 and a 200 day moving average of $4.42.

Vigil Neuroscience (NASDAQ:VIGL - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported ($0.49) earnings per share for the quarter, beating analysts' consensus estimates of ($0.53) by $0.04. On average, research analysts forecast that Vigil Neuroscience will post -2.07 earnings per share for the current fiscal year.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.